Skip to content

The effect of Sofoofe Banafshe on migraines

The effect of traditional medicine product Sofoofe Banafshe on the prevention of headaches in patients with migraine

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016110830776N1
Enrollment
86
Registered
2017-03-16
Start date
2016-10-24
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine. Use additional external cause code (Chapter XX), if desired, to identify drug, if drug-induced.

Interventions

Intervention 1: Patients in the control group receiving propranolol 20 mg twice daily plus placebo capsules 500 mg three times a day. Intervention 2: Patients in the intervention group receiving propr
Treatment - Drugs
Patients in the control group receiving propranolol 20 mg twice daily plus placebo capsules 500 mg three times a day
Patients in the intervention group receiving propranolol 20 mg twice daily plus Sofoofe Banafshe capsuls 500 mg three times a day

Sponsors

The Research Center of Neurology Diseases, Kerman University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
80 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: confirmed the diagnosis of migraine according to the criteria of IHS; 15-45 age range; patients' awareness of their disease, no pregnancy or lactation, without any other chronic diseases (heart, thyroid, hepatic, renal, neurologic, hypertension, diabetes, depression, etc.), experiencing at least four migraine attacks per month in the past few months Exclusion criteria: dislike continuing cooperation, deciding for pregnancy or having a positive pregnancy test, experiencing non-migraine headaches; non-compliance with prescribed medication

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
The number of migraine attacks per week. Timepoint: Two weeks and one month after intervention. Method of measurement: Self made questionnaire.;Severity of headache. Timepoint: Two weeks and one month after intervention. Method of measurement: VAS.;Freqency of headaches. Timepoint: Two weeks and one month after intervention. Method of measurement: Self made questionnaire.

Secondary

MeasureTime frame
Quality of life. Timepoint: Two weeks and one month after intervention. Method of measurement: SF36.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohadese Kamali

Kerman University of Medical Sciences, School of Traditional Medicine

mohadesekamali0912@gmail.com+98 34 3312 2020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026